Case Study of a 44-Year-Old Patient with a Moderate Recurrent Depressive Disorder (ICD-10 F 33.1) from Psychodynamic Point of ViewMrs. X is a 44-year-old divorced mother of one (daughter) who presented with a major depression of moderate intensity which was already chronic as she came to...
Background: Many and diverse autoimmune abnormalities have been reported in children with autism. Natural autoantibodies (NAAbs) play important immunoregulatory roles in recognition of the immune self. The objective of this study was to examine the prese
Who Can Participate The study is enrolling adults diagnosed with major depressive disorder who do not have enough relief from their current antidepressant medications. Specific criteria must be met to join the study. What Happens in the Study Participants will be randomly assigned to receive either ...
participants, show the drug was not significantly better than a placebo at improving symptoms of the most common type, known as major depression.Alto plans to analyze all the data from the study to determine the most appropriate next steps, if any, for ALTO-100 in major depressive disorder. ...
Active Indication Sleep Initiation and Maintenance Disorders Inactive Indication Attention Deficit Disorder With HyperactivityDepressive Disorder, MajorGeneralized anxiety disorder Sumitomo Pharma America, Inc. Drug Highest PhaseApproved First Approval Date ...
亚甲二氧甲基苯丙胺: 一种5-HT2A receptor激动剂、SERT抑制剂药物,由MAPS Europe B.V. (MAPS Europe B.V.)公司最早进行研发,目前全球最高研发状态为临床3期,作用机制: 5-HT2A receptor激动剂(5-羟色胺2A受体激动剂),SERT抑制剂(5-羟色胺转运体抑制剂),治疗领域: 其他疾